Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments [PDF]
Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed.
core +2 more sources
Non‐small cell lung cancer in China
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer
Peixin Chen +3 more
doaj +1 more source
Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael +8 more
core +1 more source
Non-small-cell lung cancer: how to manage BRAF-mutated disease
BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes
Giorgia Guaitoli +5 more
doaj +1 more source
MYC is a metastasis gene for non-small-cell lung cancer. [PDF]
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn +26 more
core +1 more source
Immunotherapy of lung cancer: An update [PDF]
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A. +15 more
core +1 more source
Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]
Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Hennen, Elisabeth +19 more
core +1 more source
Prognostic significance of folate metabolism polymorphisms for lung cancer. [PDF]
Functional nonsynonymous single-nucleotide polymorphisms (nsSNPs) of folate metabolism genes can influence the methylation of tumour suppressor genes, thereby potentially impacting on tumour behaviour.
El Galta, R +13 more
core +1 more source
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G. +25 more
core +1 more source
Staging non-small cell lung cancer [PDF]
Patients with newly diagnosed non-small cell lung cancer (NSCLC) need accurate tumor staging in order to direct appropriate therapy and establish prognosis; the tumor is usually staged using the TNM system. The major imaging modalities currently used for staging this disease are thoracic computed tomography (CT) (including the adrenal glands) and whole
openaire +2 more sources

